Tenaya Therapeutics

9 articles about Tenaya Therapeutics

• Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress

  10/12/2021

  Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that it will present new preclinical data at the virtual 28th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), October 19 - 22, 2021.

• Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

  9/8/2021

  Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today reported business and program updates and second quarter 2021 financial results.

• 

  Biotech IPO Stampede Continues with Five More Companies

  7/12/2021

  The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange. 

• Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy

  5/11/2020

  Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver potentially curative therapies that target the underlying causes of heart disease, today announced that it will present preclinical data from four studies as posters at the 23 rd Annual Meeting of the American Society of Gene & Cell T

• Tenaya Therapeutics Closes $92 Million Series B Financing

  10/3/2019

  Proceeds advance heart disease projects from three product platforms toward the clinic

• Tenaya Therapeutics Strengthens Leadership Team with Appointment of Two Biopharmaceutical Industry Veterans

  3/13/2019

  Tenaya Therapeutics, a biopharmaceutical company focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team with the appointment of Whittemore Tingley, M.D., Ph.D., as Chief Medical Officer, and Kee-Hong Kim, Ph.D., as Senior Vice President of Manufacturing and Technical Operations.

• Tenaya Therapeutics Appoints Faraz Ali as Chief Executive Officer

  7/30/2018

  Tenaya Therapeutics is a preclinical-stage biotechnology company focused on discovery and development of novel therapies for heart failure

• Tenaya Therapeutics Appoints Tim Hoey, Ph.D. as CSO

  11/1/2017

  Dr. Hoey is a biopharmaceutical executive with over two decades of experience in the industry.

• Gladstone Institute Spinout Tenaya Therapeutics Launches With $50 Million

  12/8/2016